Warby Parker stock declines amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy WRBY?
Warby Parker Inc. shares fell sharply, crossing below the 5-day SMA, reflecting a significant decline in investor confidence.
The stock's drop comes amid broader market weakness, with the Nasdaq-100 down 0.72% and the S&P 500 down 0.75%. This sector rotation indicates that investors are moving away from growth stocks like Warby Parker in favor of more stable investments.
As the market continues to show signs of weakness, Warby Parker may face further challenges in regaining investor trust and stabilizing its stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WRBY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WRBY
Wall Street analysts forecast WRBY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WRBY is 26.36 USD with a low forecast of 18.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 23.810
Low
18.00
Averages
26.36
High
35.00
Current: 23.810
Low
18.00
Averages
26.36
High
35.00
About WRBY
Warby Parker Inc. is a lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company offers holistic vision care by selling eyewear products and providing optical services directly to consumers through its retail stores and e-commerce platform. It sells a range of prescription and non-prescription eyewear, including glasses, sunglasses, and contact lenses. Its customers can customize their prescription lenses with a variety of options, including single-vision, progressive, light-responsive, blue-light-filtering, and non-prescription lenses. It also offers in-house technologies like Virtual Vision Test and Virtual Try-On to enhance the overall customer experience. It sells its own brand of contacts, Scout by Warby Parker, and third-party contact lenses; this allows it to provide customers with a vision care offering. Its Website and mobile app make it easy for its customers to browse, virtually try on, and purchase glasses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bullish Appoints Lindsay Kaplan as Venture Partner to Support Next-Gen Consumer Brands
- Strategic Partnership Strengthened: Bullish's appointment of Lindsay Kaplan as Venture Partner underscores its ongoing commitment to consumer businesses that shape markets and culture, which is expected to enhance the firm's influence in consumer investing.
- Rich Industry Experience: With over a decade in consumer branding, Kaplan's role in growing Chief into a billion-dollar brand is anticipated to bring valuable market insights and brand-building capabilities to Bullish.
- Innovative Investment Strategy: By combining capital with deep brand expertise, Bullish aims to identify potential breakout consumer companies, which is expected to further drive growth and market adaptability within its investment portfolio.
- Brand-Driven Value: Kaplan emphasizes that Bullish's investments go beyond financial support, involving deep collaboration with founders to shape and strengthen brand strategies, thereby enhancing long-term enterprise value and market competitiveness.
See More
Warby Parker CEO David Gilboa Sells 94,906 Shares for $2.6 Million
- Insider Selling: Warby Parker Co-CEO David Gilboa sold 94,906 shares on January 7 and 9, 2026, for approximately $2.6 million, indicating a trend of reducing his stake in the company.
- Ownership Shift: Following this transaction, Gilboa's direct holdings fell to 37,247 shares, valued at about $1.1 million based on the January 9, 2026 market close, while he still retains significant indirect ownership through a trust.
- Transaction Details: The shares sold were acquired through the conversion of derivative securities (options) and immediately sold as Class A Common Stock, highlighting a derivative-driven liquidation rather than a discretionary sale of long-held stock.
- Market Implications: Although the sale occurred after the stock reached a 52-week high of $31, it was part of a prearranged Rule 10b5-1 trading plan, alleviating concerns and reflecting the company's positive outlook following its AI-powered eyewear announcement.
See More
Warby Parker CEO David Gilboa Sells 94,906 Shares for $2.6 Million
- Large Transaction: Warby Parker's Co-CEO David Gilboa sold 94,906 shares in January 2026 at a weighted average price of $27.51, totaling approximately $2.6 million, reducing his direct holdings to 37,247 shares, which now represent just 0.03% of the company's total shares outstanding.
- Transaction Context: This sale was executed under a prearranged Rule 10b5-1 trading plan established in September 2025, aimed at avoiding insider trading allegations; despite the reduction in direct holdings, he still indirectly owns nearly 1.7 million shares through a trust, indicating confidence in the company's long-term prospects.
- Performance Recovery: Warby Parker reported third-quarter revenue of $221.7 million, a 15% year-over-year increase, with a net income of $5.9 million, marking a significant turnaround from a net loss of $4.1 million in the previous year, showcasing the company's competitive strength and improving profitability.
- Market Reaction: Following the announcement of AI-powered eyeglasses, Warby Parker's stock reached a 52-week high of $31 on December 11, 2025; however, with a forward P/E ratio of 62, the stock appears expensive, suggesting investors should wait for a price correction before considering new investments.
See More
Warby Parker (WRBY) Stock Surpasses Analyst Target Price of $26.92, Trading at $29.09
- Price Breakthrough: Warby Parker Inc (WRBY) shares have surpassed the average analyst 12-month target price of $26.92, currently trading at $29.09, indicating market optimism about its future performance.
- Analyst Reactions: As the stock exceeds the target price, analysts may choose to downgrade valuations or raise target prices, reflecting potential improvements in the company's fundamentals that could influence investor decisions.
- Target Price Distribution: Among the 13 analysts covered by Zacks, target prices range from $18.00 to $35.00, with a standard deviation of $5.514, illustrating varying market perspectives on WRBY's future performance.
- Investor Signal: The rise in WRBY's stock price provides investors with a good signal to reassess the company, prompting them to consider whether the current valuation is justified or if it is time to take profits.
See More
Vanguard Small-Cap Growth ETF Components: Warby Parker Rises 11.3%
- Highest Volume Component: Plug Power saw a rise of about 2.9% on Tuesday with over 31 million shares traded, indicating strong market interest in its growth potential, which may attract more investors.
- Opendoor Technologies Performance: The company’s stock fell approximately 3.1% with over 25.3 million shares changing hands, reflecting market concerns about its future profitability, potentially impacting its short-term investment appeal.
- Warby Parker's Strong Performance: The stock surged by about 11.3%, making it the best performer on Tuesday, showcasing strong demand and brand recognition in the market, which could drive future growth potential.
- Irhythm Technologies Underperformance: The stock declined by about 8.5%, lagging behind other components in the Vanguard Small-Cap Growth ETF, possibly reflecting market doubts about its business model or financial health, affecting investor confidence.
See More
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
See More
Bullish Appoints Lindsay Kaplan as Venture Partner to Support Next-Gen Consumer Brands
- Strategic Partnership Strengthened: Bullish's appointment of Lindsay Kaplan as Venture Partner underscores its ongoing commitment to consumer businesses that shape markets and culture, which is expected to enhance the firm's influence in consumer investing.
- Rich Industry Experience: With over a decade in consumer branding, Kaplan's role in growing Chief into a billion-dollar brand is anticipated to bring valuable market insights and brand-building capabilities to Bullish.
- Innovative Investment Strategy: By combining capital with deep brand expertise, Bullish aims to identify potential breakout consumer companies, which is expected to further drive growth and market adaptability within its investment portfolio.
- Brand-Driven Value: Kaplan emphasizes that Bullish's investments go beyond financial support, involving deep collaboration with founders to shape and strengthen brand strategies, thereby enhancing long-term enterprise value and market competitiveness.
See More
Warby Parker CEO David Gilboa Sells 94,906 Shares for $2.6 Million
- Insider Selling: Warby Parker Co-CEO David Gilboa sold 94,906 shares on January 7 and 9, 2026, for approximately $2.6 million, indicating a trend of reducing his stake in the company.
- Ownership Shift: Following this transaction, Gilboa's direct holdings fell to 37,247 shares, valued at about $1.1 million based on the January 9, 2026 market close, while he still retains significant indirect ownership through a trust.
- Transaction Details: The shares sold were acquired through the conversion of derivative securities (options) and immediately sold as Class A Common Stock, highlighting a derivative-driven liquidation rather than a discretionary sale of long-held stock.
- Market Implications: Although the sale occurred after the stock reached a 52-week high of $31, it was part of a prearranged Rule 10b5-1 trading plan, alleviating concerns and reflecting the company's positive outlook following its AI-powered eyewear announcement.
See More
Warby Parker CEO David Gilboa Sells 94,906 Shares for $2.6 Million
- Large Transaction: Warby Parker's Co-CEO David Gilboa sold 94,906 shares in January 2026 at a weighted average price of $27.51, totaling approximately $2.6 million, reducing his direct holdings to 37,247 shares, which now represent just 0.03% of the company's total shares outstanding.
- Transaction Context: This sale was executed under a prearranged Rule 10b5-1 trading plan established in September 2025, aimed at avoiding insider trading allegations; despite the reduction in direct holdings, he still indirectly owns nearly 1.7 million shares through a trust, indicating confidence in the company's long-term prospects.
- Performance Recovery: Warby Parker reported third-quarter revenue of $221.7 million, a 15% year-over-year increase, with a net income of $5.9 million, marking a significant turnaround from a net loss of $4.1 million in the previous year, showcasing the company's competitive strength and improving profitability.
- Market Reaction: Following the announcement of AI-powered eyeglasses, Warby Parker's stock reached a 52-week high of $31 on December 11, 2025; however, with a forward P/E ratio of 62, the stock appears expensive, suggesting investors should wait for a price correction before considering new investments.
See More
Warby Parker (WRBY) Stock Surpasses Analyst Target Price of $26.92, Trading at $29.09
- Price Breakthrough: Warby Parker Inc (WRBY) shares have surpassed the average analyst 12-month target price of $26.92, currently trading at $29.09, indicating market optimism about its future performance.
- Analyst Reactions: As the stock exceeds the target price, analysts may choose to downgrade valuations or raise target prices, reflecting potential improvements in the company's fundamentals that could influence investor decisions.
- Target Price Distribution: Among the 13 analysts covered by Zacks, target prices range from $18.00 to $35.00, with a standard deviation of $5.514, illustrating varying market perspectives on WRBY's future performance.
- Investor Signal: The rise in WRBY's stock price provides investors with a good signal to reassess the company, prompting them to consider whether the current valuation is justified or if it is time to take profits.
See More
Vanguard Small-Cap Growth ETF Components: Warby Parker Rises 11.3%
- Highest Volume Component: Plug Power saw a rise of about 2.9% on Tuesday with over 31 million shares traded, indicating strong market interest in its growth potential, which may attract more investors.
- Opendoor Technologies Performance: The company’s stock fell approximately 3.1% with over 25.3 million shares changing hands, reflecting market concerns about its future profitability, potentially impacting its short-term investment appeal.
- Warby Parker's Strong Performance: The stock surged by about 11.3%, making it the best performer on Tuesday, showcasing strong demand and brand recognition in the market, which could drive future growth potential.
- Irhythm Technologies Underperformance: The stock declined by about 8.5%, lagging behind other components in the Vanguard Small-Cap Growth ETF, possibly reflecting market doubts about its business model or financial health, affecting investor confidence.
See More
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
See More
